Over the 12-year study period, cystatin C was measured in only 1869 patients with cancer, whereas more than 770 000 patients with cancer had their SCr checked (approximately 0.2% of the population had concurrent eGFRcr and eGFRcys) over the same period (eFigure 1 in Supplement 1). The gene discussed is CST3; the disease is cancer.